Akouos IPO Presentation Deck

Offering Summary Issuer / Ticker Common Stock Offered Estimated Gross Proceeds Over-Allotment Option Price Range Use of Proceeds Lock-Up Period Bookrunners Co-Manager • Akouos, Inc., AKUS (NASDAQ) • 8,333,333 shares (100% Primary) . $125 million at the midpoint 15% (100% Primary) $14-$16 • Advance the clinical development of AK-OTOF for the treatment of OTOF-mediated hearing loss through the report of preliminary clinical data from our planned Phase 1/2 clinical trial; • Initiate clinical development of our additional product candidates, anti-VEGF, CLRN1, and GJB2; • Continue preclinical development of our other product candidates and development programs, including our autosomal dominant hearing disorder and our hair cell regeneration programs, and to continue development of our platform; • Establish internal manufacturing capabilities of 250-liter capacity; The remainder for working capital and other general corporate purposes 180 days for Akouos, directors, executive officers, and existing security holders • BofA Securities, Cowen and Piper Sandler & Co. BTIG AKOUOS

View entire presentation